{"id":"tuberculin","rwe":[{"pmid":"41910258","year":"2026","title":"From T-cell sensitization to molecular-intelligent stratification: a roadmap for precision diagnosis of latent tuberculosis infection.","finding":"","journal":"Clinical microbiology reviews","studyType":"Clinical Study"},{"pmid":"41908889","year":"2026","title":"Isolated ovarian tuberculosis in a hemodialysis patient: An incidental pre-transplant discovery with diagnostic and management implications.","finding":"","journal":"IDCases","studyType":"Clinical Study"},{"pmid":"41906503","year":"2026","title":"The potential of ancient medicine - using products from snails in treatment of oncology patients.","finding":"","journal":"Annals of agricultural and environmental medicine : AAEM","studyType":"Clinical Study"},{"pmid":"41898483","year":"2026","title":"Delayed-Type Hypersensitivity to Mycobacterium tuberculosis Antigens: The Immunological Mechanism and Potential Therapeutic Strategies-A Systematic Review.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"41897686","year":"2026","title":"Comparative Diagnostic Performance of TST and IGRAs in the Diagnosis of Latent Tuberculosis Infection: A Systematic Review and Diagnostic Meta-Analysis.","finding":"","journal":"Diagnostics (Basel, Switzerland)","studyType":"Clinical Study"}],"_fda":{"id":"a97e057f-6554-4ce2-bc75-3ebc1978e0d0","set_id":"1e91a67c-1694-4523-9548-58f7a8871134","openfda":{"nui":["N0000184316","N0000184315","N0000184306","M0001408"],"unii":["I7L8FKN87J"],"route":["INTRADERMAL"],"rxcui":["313532","798408"],"spl_id":["a97e057f-6554-4ce2-bc75-3ebc1978e0d0"],"brand_name":["Aplisol"],"spl_set_id":["1e91a67c-1694-4523-9548-58f7a8871134"],"package_ndc":["42023-104-01","42023-104-05"],"product_ndc":["42023-104"],"generic_name":["TUBERCULIN PURIFIED PROTEIN DERIVATIVE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Antigens, Bacterial [CS]"],"pharm_class_pe":["Cell-mediated Immunity [PE]"],"substance_name":["TUBERCULIN PURIFIED PROTEIN DERIVATIVE"],"pharm_class_epc":["Skin Test Antigen [EPC]","Tuberculosis Skin Test [EPC]"],"manufacturer_name":["ENDO USA, Inc."],"application_number":["BLA103782"],"is_original_packager":[true]},"version":"11","warnings":["WARNINGS Aplisol should not be administered to persons who previously experienced a severe reaction (e.g., vesiculation, ulceration, or necrosis) because of the severity of reactions that may occur at the test site (see CONTRAINDICATIONS ). Not all infected persons will have a delayed hypersensitivity reaction to a tuberculin test. A number of factors have been reported to cause a decreased ability to respond to the tuberculin test, such as the presence of infections, viral infections (measles, mumps, chickenpox, HIV), live virus vaccinations (measles, mumps, rubella and other live vaccines), bacterial infections (typhoid fever, brucellosis, typhus, leprosy, pertussis, overwhelming tuberculosis, tuberculous pleurisy), fungal infections (South American blastomycosis), drugs (corticosteroids and other immunosuppressive agents), metabolic derangements (chronic renal failure), low protein states (severe protein depletion, afibrinogenemia), age (newborns, elderly patients with waned sensitivity), stress (surgery, burns, mental illness, graft-versus-host reactions), diseases affecting lymphoid organs (Hodgkin's disease, lymphoma, chronic leukemia, sarcoidosis), and malignancy. 7,8,9 Any condition that impairs or attenuates cell mediated immunity potentially can cause a false negative reaction, including aging. 10,11 Tuberculin skin test results are less reliable in HIV-infected individuals as CD4 counts decline (see CLINICAL PHARMACOLOGY ). 3 Avoid injecting tuberculin subcutaneously. If this occurs, no local reaction develops, but a general febrile reaction and/or acute inflammation around old tuberculous lesions may occur in highly sensitive individuals."],"pregnancy":["Pregnancy Teratogenic effects: Pregnancy Category C Animal reproduction studies have not been conducted with Aplisol. It is also not known whether Aplisol can cause fetal harm when administered to a pregnant woman or can affect the reproduction capacity. Aplisol should be given to a pregnant woman only if clearly needed. However, the risk of unrecognized tuberculosis and the postpartum contact between a mother with active disease and an infant leaves the infant in grave danger of tuberculosis and complications such as tuberculous meningitis. Although there have not been any reported adverse effects upon the fetus recognized as being due to tuberculosis skin testing, the prescribing physician will want to consider if the potential benefits outweigh the possible risks for performing the tuberculin test on a pregnant woman or a woman of childbearing age, particularly in certain high risk populations. Tuberculin skin testing is considered valid and safe throughout pregnancy. 3"],"references":["REFERENCES Seibert, F.B. The isolation and properties of the purified protein derivative of tuberculin: Am Rev Tuberc 1934; 30:713. Seibert, F.B., and Glenn, J.T. Tuberculin purified protein derivative. Preparation and analyses of a large quantity for standard. Am Rev Tuberc 1941; 44:9-25. Centers for Disease Control and Prevention (CDC). Essential components of a tuberculosis prevention and control program; and Screening for tuberculosis and tuberculosis infection in high-risk populations: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1995;44(RR-11):1-34. Centers for Disease Control and Prevention (CDC). Prevention and control of tuberculosis in correctional facilities: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1996;45(RR-8):1-27. Huebner RE, Shein MF, Bass JB. The Tuberculin Skin Test. Clin Infect Dis 1993;17:968–75. AHFS Drug Information, 1997, 36:84 pp 1962–1968. American Thoracic Society: Diagnostic standards and classification of tuberculosis in Adults and Children. Am J Respir Crit Care Med 2000 Apr; 161:1376-95. Am Rev Respir Dis 1985;886. Brickman HF et.Al. The Timing of Tuberculin Tests in Relation to Immunization with Live Viral Vaccines. Pediatrics 1975;55:392. Nakayama K, Monma M, Fukushima T, Ohrui T, Sasaki H. Tuberculin responses and risk of pneumonia in immobile elderly patients. Thorax 2000 Oct;55(10):867-9. Fukushima T, Nakayama K, Monma M, Sekizawa K, Sasaki H. Depression of T helper-1 and the tuberculin responses in older bed-bound patients. J Am Geriatri Soc 1999 Feb;47(2):259-260. American Academy of Pediatrics. Tuberculosis. In: Pickering LK, CJ Baker, Long SS, McMillan JA, eds. Red Book : 2006 Report of the Committee on Infectious Diseases, 27 th ed. Elk Grove Village, IL: American Academy of Pediatrics 2006: 678-698. Landi S, Held HR. Stability of a dilute solution of tuberculin purified derivative at extreme temperatures. J Biol Stand 1981; 9:195. Centers For Disease Control and Prevention (CDC). Diagnosis of TB Infection and TB Disease, March 21,1996, Doc# 2250102. Sewell, E.M., O'Hare, D., and Kendig, E.L., Jr. The Tuberculin Test. Pediatrics Vol. 54, No. 5, Nov.1974. Centers for Disease Control and Prevention(CDC). Prevention and control of tuberculosis in facilities providing long-term care to the elderly. Recommendations of the Advisory Committee of Elimination of Tuberculosis (ACET): MMWR 1990, 39(RR-10): 7–20. Centers for Disease Control and Prevention(CDC). The use of preventative therapy for tuberculosis infection in the United States, Recommendations of the Advisory Committee of Elimination of Tuberculosis (ACET), MMWR 1990 39(RR-8):9–12. Centers for Disease Control and Prevention(CDC). Screening for tuberculosis and tuberculosis infection in high risk populations. Recommendations of the Advisory Committee of Elimination of Tuberculosis (ACET), MMWR 1990, 39(RR-8): 1-7. Centers for Disease Control and Prevention (CDC). Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. MMWR, 2000. 49(RR-6): 1-51. Pediatrics: Screening for Tuberculosis in Infants and Children, 1994. 93: 131-134. Centers for Disease Control and Prevention (CDC). Controlling Tuberculosis in the United States. MMWR 2005. 54 (RR-12)."],"description":["DESCRIPTION Aplisol (tuberculin PPD, diluted) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The solution is stabilized with polysorbate (Tween) 80, buffered with potassium and sodium phosphates and contains approximately 0.25% phenol as a preservative. This product is ready for immediate use without further dilution. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis by the method of F.B. Seibert. 1,2 Tuberculin PPD, diluted, is prepared from Tuberculin PPD which is clinically bioequivalent in potency to the standard PPD-S* (5 TU** per 0.1mL) of the U.S. Public Health Service, National Centers for Disease Control. The potency of each lot of tuberculin PPD, diluted is determined in sensitized guinea pigs."],"precautions":["PRECAUTIONS General The predictive value of the tuberculin skin test depends on the prevalence of infection with M. tuberculosis and the relative prevalence of cross-reactions with nontuberculous mycobacteria. 9,12 A separate, sterile, single-use disposable syringe and needle should be used for each individual patient to prevent possible transmission of serum hepatitis virus and other infectious agents from one person to another. Special care should be taken to ensure that the product is injected intradermally and not into a blood vessel. Before administration of Aplisol, a review of the patient's history with respect to possible immediate-type hypersensitivity to the product, determination of previous use of Aplisol and the presence of any contraindication to the test should be made (see CONTRAINDICATIONS ). As with any biological product, epinephrine should be immediately available in case an anaphylactoid or acute hypersensitivity reaction occurs. Failure to store and handle Aplisol as recommended may result in a loss of potency and inaccurate test results. 8,13 Reactivity to the test may be depressed or suppressed for as long as 5–6 weeks in individuals following immunization with certain live viral vaccines, viral infections or discontinuation of corticosteroids or immunosuppressive agents. 8,9 Information to Patients Patients should be instructed to report adverse events such as vesiculation, ulceration or necrosis which may occur at the test site in highly sensitive individuals. Patients should be informed that pain, pruritus and discomfort may occur at injection site. Patients should be informed of the need to return to their physician or health care provider for the reading of the test and of the need to keep and maintain a personal immunization record. Drug Interactions In patients who are receiving corticosteroids or immunosuppressive agents, reactivity to the test may be depressed or suppressed. This reduced reactivity may be present for as long as 5–6 weeks after discontinuation of therapy (see PRECAUTIONS – General ). 9 The reactivity to PPD may be temporarily depressed by certain live virus vaccines (measles, mumps, rubella, oral polio, yellow fever, and varicella). Therefore, if a tuberculin test is to be performed, it should be administered either before the live vaccine or given simultaneously, but at a separate site than the live vaccine, or testing should be postponed for 4–6 weeks. 9 Carcinogenesis, Mutagenesis, Impairment of Fertility No long term studies have been conducted in animals or in humans to evaluate carcinogenic or mutagenic potential or effects on fertility with Aplisol. Pregnancy Teratogenic effects: Pregnancy Category C Animal reproduction studies have not been conducted with Aplisol. It is also not known whether Aplisol can cause fetal harm when administered to a pregnant woman or can affect the reproduction capacity. Aplisol should be given to a pregnant woman only if clearly needed. However, the risk of unrecognized tuberculosis and the postpartum contact between a mother with active disease and an infant leaves the infant in grave danger of tuberculosis and complications such as tuberculous meningitis. Although there have not been any reported adverse effects upon the fetus recognized as being due to tuberculosis skin testing, the prescribing physician will want to consider if the potential benefits outweigh the possible risks for performing the tuberculin test on a pregnant woman or a woman of childbearing age, particularly in certain high risk populations. Tuberculin skin testing is considered valid and safe throughout pregnancy. 3 Geriatric Use Once acquired, tuberculin sensitivity tends to persist, although it often wanes with time and advancing age. In geriatric patients or in patients receiving a tuberculin skin test for the first time, the reaction may develop more slowly and may not be maximal until after 72 hours. 6,7 (see CLINICAL PHARMACOLOGY ). Not all infected persons will have a delayed hypersensitivity reaction to a tuberculin test. A number of factors have been reported to cause a decreased ability to respond to the tuberculin test, such as elderly patients with waned sensitivity. 7 Any condition that impairs or attenuates cell mediated immunity potentially can cause a false negative reaction, including aging 10,11 (see WARNINGS ). An induration of >10 mm is classified as positive in all persons who do not meet any of the criteria listed under an induration of >5 mm, but who belong to one or more of the following groups at high risk for TB, including residents and employees of high risk congregate settings, such as nursing homes and other long-term facilities for the elderly. The negative tuberculin skin test should never be used to exclude the possibility of active tuberculosis among person for whom the diagnosis is being considered (symptoms compatible with tuberculosis) (see DOSAGE AND ADMINISTRATION-Interpretation of Tuberculin Reaction ). Pediatric Use Because their immune systems are immature, many neonates and infants <6 weeks of age, who are infected with M. tuberculosis , may not have a delayed hypersensitivity reaction to a tuberculin test (see WARNINGS ). Older infants and children develop tuberculin sensitivity 3-6 weeks, and up to 3 months, after initial infection. 5,20 Infants and children who have been exposed to persons with active tuberculosis should be considered positive when reaction to the tuberculin skin test measures ≥ 5 mm. Those children younger than 4 years of age who are exposed to persons at increased risk to acquire tuberculosis are considered positive when reaction measures ≥10 mm. Children with minimal risk exposure to tuberculosis would be considered positive when reaction measures ≥15 mm. 5,20 Other criteria for positive tuberculin reactions that are applicable to both pediatric and adult patients are provided in DOSAGE AND ADMINISTRATION, Interpretation of Tuberculin Reaction ."],"how_supplied":["HOW SUPPLIED Tuberculin PPD-Aplisol bioequivalent to 5 US units (TU) PPD-S per test dose (0.1 mL) is available in the following presentations: NDC 42023-104-01 (Bio. 1525) 1 mL (10 tests) – multiple dose vial NDC 42023-104-05 (Bio.1607) 5 mL (50 tests) – multiple dose vial This product is ready for use without further dilution. Storage DO NOT FREEZE This product should be stored between 2° and 8°C (36° and 46°F) and protected from light. Vials in use more than 30 days should be discarded due to possible oxidation and degradation which may affect potency. *PPD-S - World Health Organization International PPD-Tuberculin Standard **U.S. Tuberculin Unit"],"geriatric_use":["Geriatric Use Once acquired, tuberculin sensitivity tends to persist, although it often wanes with time and advancing age. In geriatric patients or in patients receiving a tuberculin skin test for the first time, the reaction may develop more slowly and may not be maximal until after 72 hours. 6,7 (see CLINICAL PHARMACOLOGY ). Not all infected persons will have a delayed hypersensitivity reaction to a tuberculin test. A number of factors have been reported to cause a decreased ability to respond to the tuberculin test, such as elderly patients with waned sensitivity. 7 Any condition that impairs or attenuates cell mediated immunity potentially can cause a false negative reaction, including aging 10,11 (see WARNINGS ). An induration of >10 mm is classified as positive in all persons who do not meet any of the criteria listed under an induration of >5 mm, but who belong to one or more of the following groups at high risk for TB, including residents and employees of high risk congregate settings, such as nursing homes and other long-term facilities for the elderly. The negative tuberculin skin test should never be used to exclude the possibility of active tuberculosis among person for whom the diagnosis is being considered (symptoms compatible with tuberculosis) (see DOSAGE AND ADMINISTRATION-Interpretation of Tuberculin Reaction )."],"pediatric_use":["Pediatric Use Because their immune systems are immature, many neonates and infants <6 weeks of age, who are infected with M. tuberculosis , may not have a delayed hypersensitivity reaction to a tuberculin test (see WARNINGS ). Older infants and children develop tuberculin sensitivity 3-6 weeks, and up to 3 months, after initial infection. 5,20 Infants and children who have been exposed to persons with active tuberculosis should be considered positive when reaction to the tuberculin skin test measures ≥ 5 mm. Those children younger than 4 years of age who are exposed to persons at increased risk to acquire tuberculosis are considered positive when reaction measures ≥10 mm. Children with minimal risk exposure to tuberculosis would be considered positive when reaction measures ≥15 mm. 5,20 Other criteria for positive tuberculin reactions that are applicable to both pediatric and adult patients are provided in DOSAGE AND ADMINISTRATION, Interpretation of Tuberculin Reaction ."],"effective_time":"20240820","adverse_reactions":["ADVERSE REACTIONS In highly sensitive individuals, strongly positive reactions including vesiculation, ulceration or necrosis may occur at the test site. Cold packs or topical steroid preparations may be employed for symptomatic relief of the associated pain, pruritus and discomfort. Strongly positive test reactions may result in scarring at the test site. Immediate erythematous or other reactions may occur at the injection site. Local hypersensitivity reactions may occur at the injection site including erythema, pruritus, edema, urticaria and rash. Systemic allergic reactions including anaphylaxis/anaphylactoid reactions have been reported to occur in association with the use of Aplisol. The reactions, including anaphylaxis, generally occurred within 24 hours of exposure and manifestations included rash, urticaria, edema/angioedema and pruritus. To report SUSPECTED ADVERSE REACTIONS, contact Endo at 1-800-828-9393 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ."],"contraindications":["CONTRAINDICATIONS Aplisol is contraindicated in patients with known hypersensitivity or allergy to Aplisol or any of its components. Aplisol should not be administered to persons who have previously experienced a severe reaction (e.g., vesiculation, ulceration, or necrosis) because of the severity of reactions that may occur at the test site."],"drug_interactions":["Drug Interactions In patients who are receiving corticosteroids or immunosuppressive agents, reactivity to the test may be depressed or suppressed. This reduced reactivity may be present for as long as 5–6 weeks after discontinuation of therapy (see PRECAUTIONS – General ). 9 The reactivity to PPD may be temporarily depressed by certain live virus vaccines (measles, mumps, rubella, oral polio, yellow fever, and varicella). Therefore, if a tuberculin test is to be performed, it should be administered either before the live vaccine or given simultaneously, but at a separate site than the live vaccine, or testing should be postponed for 4–6 weeks. 9"],"general_precautions":["General The predictive value of the tuberculin skin test depends on the prevalence of infection with M. tuberculosis and the relative prevalence of cross-reactions with nontuberculous mycobacteria. 9,12 A separate, sterile, single-use disposable syringe and needle should be used for each individual patient to prevent possible transmission of serum hepatitis virus and other infectious agents from one person to another. Special care should be taken to ensure that the product is injected intradermally and not into a blood vessel. Before administration of Aplisol, a review of the patient's history with respect to possible immediate-type hypersensitivity to the product, determination of previous use of Aplisol and the presence of any contraindication to the test should be made (see CONTRAINDICATIONS ). As with any biological product, epinephrine should be immediately available in case an anaphylactoid or acute hypersensitivity reaction occurs. Failure to store and handle Aplisol as recommended may result in a loss of potency and inaccurate test results. 8,13 Reactivity to the test may be depressed or suppressed for as long as 5–6 weeks in individuals following immunization with certain live viral vaccines, viral infections or discontinuation of corticosteroids or immunosuppressive agents. 8,9"],"teratogenic_effects":["Teratogenic effects: Pregnancy Category C Animal reproduction studies have not been conducted with Aplisol. It is also not known whether Aplisol can cause fetal harm when administered to a pregnant woman or can affect the reproduction capacity. Aplisol should be given to a pregnant woman only if clearly needed. However, the risk of unrecognized tuberculosis and the postpartum contact between a mother with active disease and an infant leaves the infant in grave danger of tuberculosis and complications such as tuberculous meningitis. Although there have not been any reported adverse effects upon the fetus recognized as being due to tuberculosis skin testing, the prescribing physician will want to consider if the potential benefits outweigh the possible risks for performing the tuberculin test on a pregnant woman or a woman of childbearing age, particularly in certain high risk populations. Tuberculin skin testing is considered valid and safe throughout pregnancy. 3"],"storage_and_handling":["Storage DO NOT FREEZE This product should be stored between 2° and 8°C (36° and 46°F) and protected from light. Vials in use more than 30 days should be discarded due to possible oxidation and degradation which may affect potency. *PPD-S - World Health Organization International PPD-Tuberculin Standard **U.S. Tuberculin Unit"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY In the United States, the prevalence of Mycobacterium tuberculosis infection and active disease varies for different segments of the population; however, the risk for M. tuberculosis infection in the overall population is low. Tuberculosis (TB) case rates declined steadily for decades in the United States. However, in 1985 the TB case rate stabilized and subsequently increased through 1992, accompanied by a 14% increase in the TB mortality rate in 1988. This has been attributed to several complex social and medical factors, including the human immunodeficiency virus (HIV) epidemic, the occurrence of TB in foreign-born persons from countries that have a high prevalence of TB, the emergence of drug-resistant strains of TB, and the transmission of M. tuberculosis in congregate settings (e.g., health-care facilities, correctional facilities, drug-treatment centers, and homeless shelters). Because the overall risk of acquiring M. tuberculosis is low for the total U.S. population, the primary strategy for preventing and controlling TB in the United States is to minimize the risk of transmission by the early identification and treatment of patients who have active infectious TB, finding and screening persons who have been in contact with active infectious TB patients and screening high risk populations. Tuberculin PPD is indicated as an aid in the detection of infection with Mycobacterium tuberculosis . 3,4 After a person becomes infected with mycobacteria, T lymphocytes proliferate and become sensitized. These sensitized T cells enter the bloodstream and circulate for months or years. This sensitization process occurs principally in the regional lymph nodes and may take 2–10 weeks to develop following infection. Once acquired, tuberculin sensitivity tends to persist, although it often wanes with time and advancing age. The injection of tuberculin into the skin stimulates the lymphocytes and activates the series of events leading to a delayed-type hypersensitivity (DTH) response. This response is called \"delayed\" because the reaction becomes evident hours after injection. Dermal reactivity involves vasodilation, edema, and the infiltration of lymphocytes, basophils, monocytes, and neutrophils into the site of antigen injection. Antigen-specific T lymphocytes proliferate and release lymphokines, which mediate the accumulation of other cells at the site. The area of induration reflects DTH activity. 5 In most tuberculin-sensitive individuals, the delayed hypersensitivity reaction is evident 5–6 hours after administration of a tuberculin skin test and is maximal 48–72 hours. In geriatric patients or in patients receiving a tuberculin skin test for the first time, the reaction may develop more slowly and may not be maximal until after 72 hours. 6,7 Because their immune systems are immature, many neonates and infants <6 weeks of age, who are infected with M. tuberculosis , do not react at all to tuberculin tests. 5 Immediate erythematous or other hypersensitivity reactions to tuberculin or the constituents of the diluent may occur at the injection site. A possible decrease in responsiveness to skin testing may occur in the presence of infections, viral infections (measles, mumps, chickenpox, HIV), live virus vaccinations (measles, mumps, rubella, oral polio, varicella, yellow fever), bacterial infections (typhoid fever, brucellosis, typhus, leprosy, pertussis, overwhelming tuberculosis, tuberculous pleurisy), fungal infections (South American blastomycosis), drugs (corticosteroids and other immunosuppressive agents), metabolic derangements (chronic renal failure), low protein states (severe protein depletion, afibrinogenemia), age (newborns, elderly patients with waned sensitivity), stress (surgery, burns, mental illness, graft-versus-host reactions), diseases affecting lymphoid organs (Hodgkin's disease, lymphoma, chronic leukemia, sarcoidosis) and malignancy (see WARNINGS ). Tuberculin skin-test results are also less reliable as CD4 counts decline in HIV infected individuals. 3 The 5TU dose of Tuberculin PPD intradermally (Mantoux) is indicated as an aid in the detection of infection with Mycobacterium tuberculosis . Reactions to the Mantoux test are interpreted on the basis of a quantitative measurement of the response to a specific dose (5 TU PPD-S or equivalent) of Tuberculin PPD. 7 To determine that the Tuberculin PPD is clinically bioequivalent in potency to standard 5TU PPD-S*, 3 dose-response studies were conducted in the following populations (1) persons with a history of bacteriologically confirmed TB; (2) healthy volunteers; and (3) volunteers with active or previously active nontuberculosis mycobacterial lung disease."],"indications_and_usage":["INDICATIONS AND USAGE Tuberculin PPD is indicated as an aid in the detection of infection with Mycobacterium tuberculosis . The standard tuberculin test employs the intradermal (Mantoux) test using a 5 TU dose of tuberculin PPD. 7 The 0.1 mL test dose of Aplisol (tuberculin PPD, diluted) is equivalent to the 5 TU dose which has been clinically utilized and standardized with PPD-S. Tuberculin skin testing is not contraindicated for persons who have been vaccinated with BCG and the skin-test results of such persons are used to support or exclude the diagnosis of M. tuberculosis infections. 4 HIV infection is a strong risk factor for the development of TB disease in persons having TB infection. All HIV-infected persons should receive a PPD-tuberculin skin test. 3"],"information_for_patients":["Information to Patients Patients should be instructed to report adverse events such as vesiculation, ulceration or necrosis which may occur at the test site in highly sensitive individuals. Patients should be informed that pain, pruritus and discomfort may occur at injection site. Patients should be informed of the need to return to their physician or health care provider for the reading of the test and of the need to keep and maintain a personal immunization record."],"spl_unclassified_section":["Diagnostic Antigen For Intradermal Injection Only","Rx only. Manufactured by: Endo USA Rochester, MI 48307 U.S. License No. 2362 © 2024 Endo, Inc. or one of its affiliates. R05/2024"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Aplisol vials should be inspected visually for both particulate matter and discoloration prior to administration and discarded if either is seen. Vials in use for more than 30 days should be discarded. The 0.1 mL dose of Aplisol (tuberculin PPD, diluted) is equivalent to the 5 tuberculin units (TU) dose of Tuberculin PPD, which is the standard strength used for intradermal Mantoux testing. Standard Method (Mantoux Test) The Mantoux test is performed by intradermally injecting, on the volar aspect of the forearm, with a syringe and needle, exactly 0.1 mL of Aplisol. The result is read 48 to 72 hours later and palpable induration only is considered in interpreting the test . Induration is a hard, raised area with clearly defined margins at and around the injection site (see Interpretation of Tuberculin Reaction ). Erythema may develop at the injection site but has no diagnostic value. The standard test is performed as follows: The site of the test is usually the volar or dorsal surface of the forearm about 4\" below the elbow. Other skin sites may be used, but the volar surface of the forearm is preferred. The use of a skin area free of lesions and away from any veins is recommended. 7 The skin at the injection site is cleansed with 70% alcohol and allowed to dry. The test material is administered with a tuberculin syringe (0.5 or 1.0 mL) fitted with a short (1/4 to 1/2\") 27 gauge needle. A separate, sterile, single-use disposable syringe and needle should be used for each individual patient. The diaphragm of the vial-stopper should be wiped with 70% alcohol. The needle is inserted through the stopper diaphragm of the inverted vial. Exactly 0.1 mL is filled into the syringe with care being taken to exclude air bubbles and to maintain the lumen of the needle filled. The point of the needle is inserted into the most superficial layers of the skin with the needle bevel pointed upward. As the Tuberculin solution is injected, a pale bleb 6 to 10 mm in size (1/3\") will rise over the point of the needle. This is quickly absorbed and no dressing is required. There may be a drop of blood when the needle is withdrawn. This is normal. Use a gauze pad and gently dab to remove the blood. Do not press down as this may squeeze out the tuberculin thereby disrupting the test. In the event the injection is delivered subcutaneously (i.e., no bleb will form), or if a significant part of the dose leaks from the injection site, the test should be repeated immediately at another site at least 5 cm (2\") removed from the initial injection site. Interpretation of Tuberculin Reaction Readings of Mantoux reactions should be made by a trained health professional during the period from 48 to 72 hours after the injection. Induration only should be considered in interpreting the test. The diameter of induration should be measured transversely to the long axis of the forearm and recorded in millimeters. Erythema has no diagnostic value and should be disregarded. The presence and size of necrosis and edema if present should be recorded although not used in the interpretation of the test. In the absence of induration, an area of erythema greater than 10 mm in diameter may indicate the injection was made too deeply and retesting is indicated. Find the margins of the induration by drawing the index or middle finger lightly across the reaction. The tip of a ballpoint pen pushed at a 45° angle toward the site of injection will also stop at the edges of induration. The diameter of induration should be measured (preferable with a caliper) transversely to the long axis of the forearm and recorded in millimeters. Erythema has no diagnostic value and should be disregarded. The absence of induration should be recorded as \"0 mm\" not \"negative\". Reactions should be interpreted as follows (Please refer to most recent guidelines): Based on current guidelines, 3,7,14, 19 interpretation of reactions is as follows: Positive reactions: Reaction ≥ 5 mm of Induration Reaction ≥ 10 mm of Induration Reaction ≥ 15 mm of Induration Human immunodeficiency virus (HIV)-positive persons Recent immigrants (i.e., within the last 5 yr) from high prevalence countries Persons with no risk factors for TB Recent contacts of tuberculosis (TB) case patients Injection drug users Fibrotic changes on chest radiograph consistent with prior TB Residents and employees For persons who are otherwise at low risk and are tested at the start of employment, a reaction of ≥ 15 mm induration is considered positive. of the following high-risk congregate settings: prisons and jails, nursing homes and other long-term facilities for the elderly, hospitals and other health care facilities, residential facilities for patients with acquired immunodeficiency syndrome (AIDS), and homeless shelters Patients with organ transplants and other immunosuppressed patients (receiving the equivalent of ≥ 15 mg/d of prednisone for 1 mo or more) Risk of TB in patients treated with corticosteroids increases with higher dose and longer duration. 19 Mycobacteriology laboratory personnel Persons with the following clinical conditions that place them at high risk: silicosis, diabetes mellitus, chronic renal failure, some hematological disorders (e.g., leukemias and lymphomas), other specific malignancies (e.g., carcinoma of the head or neck and lung), weight loss of ≥ 10% of ideal body weight, gastrectomy, and jejunoileal bypass Children younger than 4 yr of age or infants, children, and adolescents exposed to adults at high-risk Skin test conversions For persons with negative skin test reactions who undergo repeat skin testing (e.g., health care workers), an increase in reaction size ≥ 10 mm within a period of 2 years should be considered a skin test conversion indicative of recent infection with M. tuberculosis . 19 In some individuals who have been infected with nontuberculous mycobacteria or have undergone BCG vaccination, the skin test may show some degree of induration. For these individuals, a conversion to \"positive\" is defined as an increase in induration by 10 mm on subsequent tests. 7 Healthcare facilities and other high-risk settings For health care workers and employees in other high-risk settings with no other risk factors for TB, a cut-off of 15 mm of induration (rather than 10 mm) on the tuberculin skin test should be used to define a positive baseline test at the time of initial employment. An increase of ≥10 mm in reaction size is generally accepted as a positive test result on subsequent testing unless the worker is a contact of a TB case or has HIV infection or is otherwise immunocompromised, in which case a result of ≥5 mm is considered positive. 21 Negative Reaction A negative reaction is an induration of less than 15 mm in persons with no risk factors for TB. This indicates a lack of hypersensitivity to tuberculoprotein and tuberculous infection is highly unlikely. 7 It should be noted that reactivity to tuberculin may be depressed or suppressed for as long as 5–6 weeks by viral infections, live virus vaccines (i.e., measles, smallpox, polio, rubella and mumps), or after discontinuation of therapy with corticosteroids or immunosuppressive agents. Malnutrition may also have a similar effect (see WARNINGS ). When of diagnostic importance, a negative test should be accepted as proof that hypersensitivity is absent only after normal reactivity to non-specific irritants has been demonstrated. A primary injection of tuberculin may possibly have a boosting effect on subsequent tuberculin reactions. A pediatric patient who is known to have been exposed to a person with tuberculosis must not be adjudged free of infection until that patient has a negative tuberculin reaction at least ten weeks after contact with tuberculous person has ceased. 17 Annual testing is generally recommended for pediatric patients in high risk populations, such as persons from countries with a high prevalence of tuberculosis and low-income groups. 18 A positive tuberculin reaction does not necessarily signify the presence of active disease. Further diagnostic procedures (e.g., chest radiograph, sputum smear and/or culture examination) should be carried out before a diagnosis of tuberculosis is made. A small percentage of responders may not have been infected with M. tuberculosis but by some other mycobacterium. The negative tuberculin skin test should never be used to exclude the possibility of active tuberculosis among persons for whom the diagnosis is being considered (symptoms compatible with tuberculosis). Booster Effect and Two-Step Testing Infection of an individual with tubercle bacilli or other mycobacteria or BCG vaccination results in a delayed hypersensitivity response to tuberculin which is demonstrated by the skin test. The delayed hypersensitivity response may gradually wane over a period of years. If a person receives a tuberculin test at this time, a significant reaction may not be detected. However, the stimulus of the test may boost or increase the size of the reaction to a second test, sometimes causing an apparent conversion or development of sensitivity. This booster effect can be seen on a second test done one week after the initial stimulating test and can persist for a year, and perhaps longer. When routine periodic tuberculin testing of adults is done, initially two-stage testing should be considered to minimize the likelihood of interpreting a boosted reaction as a conversion. 7,15,16 In this testing method, persons who have a negative initial skin test undergo a second tuberculin skin test 1-3 weeks after the first. Both tests should be read and recorded at 48 to 72 hours. Those individuals with a positive reaction on the second test should be considered to be previously infected, and those with a negative reaction on the second test should be considered uninfected. In these uninfected persons, a positive result on any future skin test should be interpreted as a skin test conversion. 7"],"spl_product_data_elements":["Aplisol Tuberculin Purified Protein Derivative TUBERCULIN PURIFIED PROTEIN DERIVATIVE TUBERCULIN PURIFIED PROTEIN DERIVATIVE POLYSORBATE 80 PHENOL"],"dosage_and_administration_table":["
Reaction ≥ 5 mm of IndurationReaction ≥ 10 mm of IndurationReaction ≥ 15 mm of Induration
Human immunodeficiency virus (HIV)-positive persons Recent immigrants (i.e., within the last 5 yr) from high prevalence countries Persons with no risk factors for TB
Recent contacts of tuberculosis (TB) case patients Injection drug users
Fibrotic changes on chest radiograph consistent with prior TB Residents and employeesFor persons who are otherwise at low risk and are tested at the start of employment, a reaction of ≥ 15 mm induration is considered positive.of the following high-risk congregate settings: prisons and jails, nursing homes and other long-term facilities for the elderly, hospitals and other health care facilities, residential facilities for patients with acquired immunodeficiency syndrome (AIDS), and homeless shelters
Patients with organ transplants and other immunosuppressed patients (receiving the equivalent of ≥ 15 mg/d of prednisone for 1 mo or more)Risk of TB in patients treated with corticosteroids increases with higher dose and longer duration. 19 Mycobacteriology laboratory personnel
Persons with the following clinical conditions that place them at high risk: silicosis, diabetes mellitus, chronic renal failure, some hematological disorders (e.g., leukemias and lymphomas), other specific malignancies (e.g., carcinoma of the head or neck and lung), weight loss of ≥ 10% of ideal body weight, gastrectomy, and jejunoileal bypass
Children younger than 4 yr of age or infants, children, and adolescents exposed to adults at high-risk
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 1 mL Carton NDC 42023- 104 -01 Rx Only Tuberculin, Purified Protein Derivative, Diluted Aplisol ® 5 TU/0.1 mL For Intradermal Test in the Diagnosis of Tuberculosis Stabilized Solution Latex Free 1 mL (10 tests) 1 mL carton","PRINCIPAL DISPLAY PANEL - 5 mL Carton NDC 42023- 104 -05 Rx Only Tuberculin, Purified Protein Derivative, Diluted Aplisol ® 5 TU/0.1 mL For Intradermal Test in the Diagnosis of Tuberculosis Stabilized Solution Latex Free 5 mL (50 tests) 5 mL carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility No long term studies have been conducted in animals or in humans to evaluate carcinogenic or mutagenic potential or effects on fertility with Aplisol."]},"tags":[{"label":"Skin Test Antigen [EPC]","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Intradermal","category":"route"},{"label":"Active","category":"status"},{"label":"infection with Mycobacterium tuberculosis","category":"indication"},{"label":"TB disease","category":"indication"},{"label":"M. tuberculosis infections","category":"indication"},{"label":"TB infection","category":"indication"},{"label":"ENDO USA, Inc.","category":"company"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"POOR QUALITY PRODUCT ADMINISTERED","source":"FDA FAERS","actionTaken":"390 reports"},{"date":"","signal":"PRODUCT STORAGE ERROR","source":"FDA FAERS","actionTaken":"320 reports"},{"date":"","signal":"INJECTION SITE ERYTHEMA","source":"FDA FAERS","actionTaken":"241 reports"},{"date":"","signal":"EXPIRED PRODUCT ADMINISTERED","source":"FDA FAERS","actionTaken":"148 reports"},{"date":"","signal":"ERYTHEMA","source":"FDA FAERS","actionTaken":"127 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"125 reports"},{"date":"","signal":"INJECTION SITE PRURITUS","source":"FDA FAERS","actionTaken":"121 reports"},{"date":"","signal":"INJECTION SITE INDURATION","source":"FDA FAERS","actionTaken":"114 reports"},{"date":"","signal":"NO ADVERSE EVENT","source":"FDA FAERS","actionTaken":"114 reports"},{"date":"","signal":"PRODUCT QUALITY ISSUE","source":"FDA FAERS","actionTaken":"109 reports"}],"drugInteractions":[{"url":"/drug/corticosteroids-or-immunosuppressive-agents","drug":"corticosteroids or immunosuppressive agents","action":"Avoid","effect":"depressed or suppressed reactivity to the test","source":"OpenFDA Label","drugSlug":"corticosteroids-or-immunosuppressive-agents"},{"url":"/drug/live-virus-vaccines-(measles,-mumps,-rubella,-oral-polio,-yellow-fever,-and-varicella)","drug":"live virus vaccines (measles, mumps, rubella, oral polio, yellow fever, and varicella)","action":"Avoid","effect":"temporarily depressed reactivity to PPD","source":"OpenFDA Label","drugSlug":"live-virus-vaccines-(measles,-mumps,-rubella,-oral-polio,-yellow-fever,-and-varicella)"}],"commonSideEffects":[{"effect":"Scarring","drugRate":"reported","severity":"unknown"},{"effect":"Anaphylaxis/anaphylactoid reactions","drugRate":"reported","severity":"unknown"},{"effect":"Rash","drugRate":"reported","severity":"unknown"},{"effect":"Urticaria","drugRate":"reported","severity":"unknown"},{"effect":"Edema/angioedema","drugRate":"reported","severity":"unknown"},{"effect":"Pruritus","drugRate":"reported","severity":"unknown"},{"effect":"Erythema","drugRate":"reported","severity":"unknown"},{"effect":"Necrosis","drugRate":"reported","severity":"unknown"},{"effect":"Ulceration","drugRate":"reported","severity":"unknown"},{"effect":"Vesiculation","drugRate":"reported","severity":"unknown"},{"effect":"Pain","drugRate":"reported","severity":"unknown"},{"effect":"Discomfort","drugRate":"reported","severity":"unknown"}],"contraindications":["known hypersensitivity or allergy to Aplisol or any of its components","persons who have previously experienced a severe reaction (e.g., vesiculation, ulceration, or necrosis) because of the severity of reactions that may occur at the test site"],"specialPopulations":{"Pregnancy":"Pregnancy Category C Animal reproduction studies have not been conducted with Aplisol. It is also not known whether Aplisol can cause fetal harm when administered to a pregnant woman or can affect the reproduction capacity. Aplisol should be given to a pregnant woman only if clearly needed. However, the risk of unrecognized tuberculosis and the postpartum contact between a mother with active disease and an infant leaves the infant in grave danger of tuberculosis and the infant should be evaluated for TB.","Geriatric use":"Once acquired, tuberculin sensitivity tends to persist, although it often wanes with time and advancing age. In geriatric patients or in patients receiving a tuberculin skin test for the first time, the reaction may develop more slowly and may not be maximal until after 72 hours. 6,7 (see CLINICAL PHARMACOLOGY ). Not all infected persons will have a delayed hypersensitivity reaction to a tuberculin test. A number of factors have been reported to cause a decreased ability to respond","Paediatric use":"Because their immune systems are immature, many neonates and infants <6 weeks of age, who are infected with M. tuberculosis , may not have a delayed hypersensitivity reaction to a tuberculin test. Older infants and children develop tuberculin sensitivity 3-6 weeks, and up to 3 months, after initial infection. 5,20 Infants and children who have been exposed to persons with active tuberculosis should be considered positive when reaction to the tuberculin skin test measures 5 mm or more of induration."}},"trials":[],"aliases":[],"company":"ENDO USA, Inc.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TUBERCULIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:14:42.369197+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:14:50.759950+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TUBERCULIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:14:51.534301+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:14:40.152135+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:14:40.152441+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:14:40.152469+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:14:53.090690+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108161/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:14:52.021117+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA103782","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:14:40.152476+00:00"}},"allNames":"aplisol","offLabel":[],"synonyms":["Aplisol","TUBERCULIN PURIFIED PROTEIN DERIVATIVE"],"timeline":[],"approvals":[],"brandName":"Aplisol","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"Skin Test Antigen [EPC]","explanation":"","oneSentence":"","technicalDetail":"Aplisol is a small molecule drug that acts as a skin test antigen, stimulating a delayed-type hypersensitivity reaction in individuals infected with Mycobacterium tuberculosis."},"commercial":{},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"TUBERCULIN\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=tuberculin","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tuberculin","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:34:21.821435","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:14:57.996172+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"tuberculin","indications":{"approved":[{"name":"infection with Mycobacterium tuberculosis","source":"OpenFDA Label","regulator":"FDA"},{"name":"TB disease","source":"OpenFDA Label","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"M. tuberculosis infections","source":"OpenFDA Label","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"TB infection","source":"OpenFDA Label","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06568484","phase":"PHASE2,PHASE3","title":"Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-07","conditions":["Tuberculosis, Latent"],"enrollment":2530,"completionDate":"2027-09"},{"nctId":"NCT01212003","phase":"","title":"Training Protocol on the Natural History of Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-06-30","conditions":["Mycobacterium Infections","Tuberculosis, Multidrug-Resistant","Latent Tuberculosis","Tuberculosis","Extensively Drug-Resistant Tuberculosis"],"enrollment":150,"completionDate":""},{"nctId":"NCT06593080","phase":"NA","title":"The DECIDE-TB Trial; Validation of Treatment Decision Algorithms for Childhood Tuberculosis","status":"RECRUITING","sponsor":"Chishala Chabala","startDate":"2024-06-01","conditions":["Tuberculosis","Child Health","HIV","Severe Acute Malnutrition"],"enrollment":30240,"completionDate":"2027-08-31"},{"nctId":"NCT04926922","phase":"","title":"PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-07-27","conditions":["Tuberculosis","HIV"],"enrollment":200,"completionDate":"2026-06-07"},{"nctId":"NCT07162129","phase":"NA","title":"Online Transdiagnostic Group CBT for Postpartum Depression and Anxiety","status":"ACTIVE_NOT_RECRUITING","sponsor":"McMaster University","startDate":"2025-09-09","conditions":["Postpartum Depression (PPD)","Postpartum Anxiety"],"enrollment":48,"completionDate":"2026-09"},{"nctId":"NCT04505566","phase":"PHASE1","title":"INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stephen J. Kim, MD","startDate":"2020-11-09","conditions":["Diabetic Retinopathy"],"enrollment":164,"completionDate":"2026-05"},{"nctId":"NCT03968822","phase":"PHASE4","title":"Intralipid® 20% for Reversal of Local Anesthetics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-07-26","conditions":["Anesthesia, Local"],"enrollment":18,"completionDate":"2026-10"},{"nctId":"NCT06425419","phase":"PHASE1","title":"The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2026-04-01","conditions":["Proliferative Vitreoretinopathy","Proliferative Vitreo-Retinopathy","Rhegmatogenous Retinal Detachment"],"enrollment":50,"completionDate":"2027-03-01"},{"nctId":"NCT04570332","phase":"PHASE2","title":"BO-112 With Pembrolizumab in Unresectable Malignant Melanoma","status":"COMPLETED","sponsor":"Highlight Therapeutics","startDate":"2020-12-30","conditions":["Melanoma"],"enrollment":42,"completionDate":"2024-11-04"},{"nctId":"NCT07161804","phase":"PHASE4","title":"Pilot RCT Using Homeopathic Medicines in ASD","status":"COMPLETED","sponsor":"Holistic Homoeopathic Clinic and Research Center","startDate":"2016-12-31","conditions":["Autism Spectrum Disorder (ASD)"],"enrollment":54,"completionDate":"2025-01-13"},{"nctId":"NCT05027958","phase":"EARLY_PHASE1","title":"Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-05-03","conditions":["Healthy","Latent Tuberculosis Infection (LTBI)"],"enrollment":17,"completionDate":"2024-12-08"},{"nctId":"NCT07210970","phase":"","title":"Prevalence of Latent Tuberculosis Infection Among Hemodialysis Patients","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2025-12-01","conditions":["Latent Tuberculosis Infection","End Stage Renal Disease (ESRD)","Hemodialysis"],"enrollment":200,"completionDate":"2027-12-20"},{"nctId":"NCT06796647","phase":"","title":"ESAT6/CFP10 Skin Testing for TB Infection in Rheumatologic Patients","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2025-03-19","conditions":["Tuberculosis (TB)"],"enrollment":100,"completionDate":"2028-08"},{"nctId":"NCT01611844","phase":"NA","title":"Optimization of Tuberculosis Intradermal Skin Test","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2011-09","conditions":["Healthy Volunteers"],"enrollment":59,"completionDate":"2013-04"},{"nctId":"NCT07145008","phase":"EARLY_PHASE1","title":"Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon","status":"RECRUITING","sponsor":"University of Baghdad","startDate":"2024-09-01","conditions":["Macular Edema (ME)","Non Infectious Uveitis"],"enrollment":20,"completionDate":"2026-12-01"},{"nctId":"NCT07072065","phase":"PHASE2","title":"Impact Of Intralesional Tuberculin Ppd Injection On Anogenital","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2022-04-01","conditions":["Human Papilloma Virus","Infections"],"enrollment":24,"completionDate":"2023-07-31"},{"nctId":"NCT07054697","phase":"PHASE4","title":"Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder","status":"COMPLETED","sponsor":"Aditi Chadha","startDate":"2017-01-01","conditions":["Autism Spectrum Disorder (ASD)"],"enrollment":54,"completionDate":"2025-01-15"},{"nctId":"NCT06975774","phase":"PHASE1","title":"Phase II Clinical Clical of the Pure Protein Derivatives of BCG","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-07-26","conditions":["Tuberculosis"],"enrollment":30,"completionDate":"2024-01-15"},{"nctId":"NCT06930326","phase":"NA","title":"Exosome Treatment and Hair Growth","status":"COMPLETED","sponsor":"COSMEDICIAN AP SDN BHD","startDate":"2022-11-01","conditions":["Alopecia Androgenica"],"enrollment":24,"completionDate":"2023-06-28"},{"nctId":"NCT05899179","phase":"PHASE3","title":"Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above","status":"RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-08-03","conditions":["Latent Tuberculosis Infection"],"enrollment":780,"completionDate":"2025-10-31"},{"nctId":"NCT04763265","phase":"PHASE2","title":"Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines","status":"COMPLETED","sponsor":"Croma-Pharma GmbH","startDate":"2020-06-24","conditions":["Frown Lines"],"enrollment":208,"completionDate":"2021-02-01"},{"nctId":"NCT06734299","phase":"NA","title":"A Study to Evaluate Usage of Mineral Sunscreens With Differentiated Whitening Attributes in Multi-Cultural Skin Tones","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer Inc. (J&JCI)","startDate":"2024-12-06","conditions":["Sunscreen"],"enrollment":45,"completionDate":"2025-02-14"},{"nctId":"NCT05746611","phase":"PHASE4","title":"Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-04-17","conditions":["Latent Tuberculosis Infection"],"enrollment":7500,"completionDate":"2024-05-13"},{"nctId":"NCT06587542","phase":"PHASE2,PHASE3","title":"Effectivity of Protein Purified Derivative Treatment for Anogenital Warts in HIV Patient","status":"NOT_YET_RECRUITING","sponsor":"Universitas Padjadjaran","startDate":"2024-09-15","conditions":["Anogenital Warts","HIV Infection","Tuberculin Purified Protein Derivative"],"enrollment":30,"completionDate":"2025-12-31"},{"nctId":"NCT03541499","phase":"PHASE2","title":"Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-10-23","conditions":["Pertussis","Pertussis Immunisation"],"enrollment":50,"completionDate":"2020-05-15"},{"nctId":"NCT06219525","phase":"NA","title":"Higher and Standard Doses of Enteral Zinc Supplementation in Very Preterm Infants","status":"RECRUITING","sponsor":"Prince of Songkla University","startDate":"2024-04-02","conditions":["Very Preterm Infants","Zinc Deficiency"],"enrollment":120,"completionDate":"2027-12-31"},{"nctId":"NCT01379781","phase":"NA","title":"Behavioral Change in the Mother-Infant Dyad: Preventing Postpartum Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2011-08","conditions":["Postpartum Depression"],"enrollment":54,"completionDate":"2018-02"},{"nctId":"NCT06389318","phase":"NA","title":"Buccal Midazolam Versus Intranasal Dexmedetomidine Plus Oral Chloral Hydrate in Inguinal Hernia Repair","status":"COMPLETED","sponsor":"Benha University","startDate":"2023-03-26","conditions":["Inguinal Hernia Repair"],"enrollment":80,"completionDate":"2024-04-24"},{"nctId":"NCT05807412","phase":"EARLY_PHASE1","title":"Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides","status":"COMPLETED","sponsor":"Lupo Center for Aesthetic and General Dermatology","startDate":"2023-05-01","conditions":["Rhytides"],"enrollment":10,"completionDate":"2024-02-26"},{"nctId":"NCT05756582","phase":"","title":"Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students","status":"RECRUITING","sponsor":"Eleonora Nucera","startDate":"2021-11-17","conditions":["Tuberculosis","Tuberculosis, Pulmonary","Tuberculosis Infection","Latent Tuberculosis","Health Care Associated Infection"],"enrollment":2040,"completionDate":"2026-12-15"},{"nctId":"NCT04205708","phase":"","title":"Screening Strategy for Early Diagnosis of Silicosis in At-Risk Populations in Oklahoma","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2019-01-14","conditions":["Silicosis","Pneumoconiosis; Silica"],"enrollment":183,"completionDate":"2022-06-10"},{"nctId":"NCT05284812","phase":"PHASE2","title":"A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)","status":"SUSPENDED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2022-02-10","conditions":["Tuberculosis"],"enrollment":200,"completionDate":"2024-12-31"},{"nctId":"NCT05565625","phase":"NA","title":"A Study to Evaluate the Whitening Effect of Mineral Sunscreens in Multi-Cultural Skin Tones","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer Inc. (J&JCI)","startDate":"2021-12-29","conditions":["Sunscreen"],"enrollment":97,"completionDate":"2022-03-30"},{"nctId":"NCT00278083","phase":"PHASE2","title":"TNF-alpha Directed Therapy in Asthma","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2001-10","conditions":["Asthma"],"enrollment":40,"completionDate":"2004-04"},{"nctId":"NCT05203068","phase":"NA","title":"Specificity Trial of the Recombinant Tuberculosis Allergen in BCG Vaccinated Healthy Volunteers","status":"COMPLETED","sponsor":"National Medical Research Center of Phthisiopulmonology and Infectious Diseases","startDate":"2021-11-24","conditions":["Tuberculosis"],"enrollment":150,"completionDate":"2022-01-26"},{"nctId":"NCT04528823","phase":"NA","title":"GXT - GeneXpert or Chest-X-ray or Tuberculin Skin Testing for Household Contact Assessment","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2020-01-31","conditions":["Latent Tuberculosis"],"enrollment":1589,"completionDate":"2023-06-30"},{"nctId":"NCT05941910","phase":"PHASE2","title":"The Effect of Coenzyme Q10 on Endothelial, Vascular and Myocardial Function","status":"UNKNOWN","sponsor":"Attikon Hospital","startDate":"2023-04-01","conditions":["Non-Alcoholic Fatty Liver Disease"],"enrollment":60,"completionDate":"2023-12-31"},{"nctId":"NCT04563273","phase":"PHASE1","title":"Clinical Study of BCG Vaccine for Intradermal Injection","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2020-10-21","conditions":["Tuberculosis"],"enrollment":160,"completionDate":"2022-10-30"},{"nctId":"NCT05847491","phase":"","title":"Latent Tuberculosis in Healthcare Workers - the Reality of a Portuguese Tertiary Hospital","status":"UNKNOWN","sponsor":"Centro Hospitalar do Oeste","startDate":"2022-09-01","conditions":["Tuberculosis"],"enrollment":100,"completionDate":"2023-12-31"},{"nctId":"NCT00070070","phase":"PHASE1","title":"Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2003-10-28","conditions":["Transitional Cell Carcinoma"],"enrollment":6,"completionDate":"2013-09-30"},{"nctId":"NCT05124340","phase":"PHASE2","title":"Safety and Tuberculin Conversion Following BCG Vaccination","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2021-12-01","conditions":["BCG Vaccination Reaction"],"enrollment":220,"completionDate":"2022-07-30"},{"nctId":"NCT04239313","phase":"PHASE1","title":"A Phase Ib Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2020-05-27","conditions":["Tuberculosis"],"enrollment":30,"completionDate":"2022-06-20"},{"nctId":"NCT02688309","phase":"","title":"Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2015-01-13","conditions":["Macular Edema","Fibrosis of the Retina"],"enrollment":44,"completionDate":"2021-10-28"},{"nctId":"NCT03026972","phase":"PHASE1","title":"A Phase ⅠStudy of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2018-04-16","conditions":["Tuberculosis"],"enrollment":25,"completionDate":"2019-10-30"},{"nctId":"NCT04742816","phase":"PHASE4","title":"Renal Effects of Hormones/Biomarkers in Transgender PrEP Recipients","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-09-17","conditions":["Transgender","Renal Function","Hormone Replacement Therapy"],"enrollment":42,"completionDate":"2021-12-31"},{"nctId":"NCT05254561","phase":"PHASE2,PHASE3","title":"Triple Antigen vs Monoantigen Immunotherapy for Warts","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-11-20","conditions":["Triple Intralesional Immunotherapy Combination in Multiple Recalcitrant Warts"],"enrollment":160,"completionDate":"2021-11-15"},{"nctId":"NCT00604617","phase":"","title":"Interferon-Gamma Release Assays in Tuberculosis (TB) - HIV Co-infected Children","status":"COMPLETED","sponsor":"Case Western Reserve University","startDate":"2009-01-26","conditions":["Tuberculosis","HIV"],"enrollment":564,"completionDate":"2012-08-21"},{"nctId":"NCT01977898","phase":"NA","title":"Incidence of Headache Following an Unintentional Dural Puncture","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2011-11","conditions":["Postdural Puncture Headache","Post-Lumbar Puncture Headache","Cerebrospinal Fluid Leaks"],"enrollment":68,"completionDate":"2019-03-01"},{"nctId":"NCT02090374","phase":"NA","title":"Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2014-03","conditions":["Allergic Rhinitis","Asthma","Latent Tuberculosis"],"enrollment":93,"completionDate":"2017-03"},{"nctId":"NCT00574678","phase":"PHASE1,PHASE2","title":"Analyzing the Composition of Tears to Identify Cancer","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2006-12","conditions":["Breast Cancer","Ovarian Cancer","Colon Cancer","Benign Disease"],"enrollment":150,"completionDate":"2016-02"},{"nctId":"NCT02102841","phase":"NA","title":"Investigating Immune Mechanisms in Atopic Eczema","status":"WITHDRAWN","sponsor":"University College, London","startDate":"2014-05","conditions":["Atopic Dermatitis"],"enrollment":0,"completionDate":"2017-05"},{"nctId":"NCT04632537","phase":"PHASE3","title":"BCG Vaccination to Prevent COVID-19","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2020-12-07","conditions":["COVID-19"],"enrollment":0,"completionDate":"2021-03-23"},{"nctId":"NCT02195349","phase":"PHASE1","title":"A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-30","conditions":["Psoriasis"],"enrollment":67,"completionDate":"2018-03-07"},{"nctId":"NCT01622140","phase":"","title":"Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-10","conditions":["Latent Tuberculosis Infection","Tuberculosis"],"enrollment":21334,"completionDate":"2020-12-31"},{"nctId":"NCT00600782","phase":"PHASE2","title":"Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-05","conditions":["Tuberculosis (TB)","Tuberculosis Vaccines"],"enrollment":45,"completionDate":"2008-12-19"},{"nctId":"NCT04212078","phase":"PHASE1,PHASE2","title":"Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime","status":"UNKNOWN","sponsor":"National University of Malaysia","startDate":"2019-07-29","conditions":["Endophthalmitis Postoperative"],"enrollment":138,"completionDate":"2022-10"},{"nctId":"NCT04236765","phase":"NA","title":"Tuberculosis In Children Visiting Friends and Relatives","status":"UNKNOWN","sponsor":"Hospital Mutua de Terrassa","startDate":"2018-01-01","conditions":["Tuberculosis Infection"],"enrollment":492,"completionDate":"2020-12-31"},{"nctId":"NCT03625219","phase":"NA","title":"Characterization of the Molecular Mechanisms Involved in Delayed-Type Hypersensitivity Reactions to House Dust Mite, Diphencyprone, Nickel, and Tuberculin Purified Protein Derivative in Healthy Volunteers","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2018-07-26","conditions":["Delayed Type Hypersensitivity"],"enrollment":54,"completionDate":"2020-06-09"},{"nctId":"NCT03835832","phase":"","title":"Self-Assessment Tuberculin Skin Test","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2019-06-04","conditions":["Tuberculin Skin Test"],"enrollment":215,"completionDate":"2020-05-31"},{"nctId":"NCT02430259","phase":"PHASE3","title":"Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2015-03","conditions":["Silicosis","Tuberculosis"],"enrollment":566,"completionDate":"2018-06"},{"nctId":"NCT03910946","phase":"","title":"Prevalence of Latent Tuberculosis in High Risk Children","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-07-01","conditions":["Latent Tuberculosis"],"enrollment":100,"completionDate":"2021-02"},{"nctId":"NCT00424684","phase":"NA","title":"Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation","status":"WITHDRAWN","sponsor":"University of Pittsburgh","startDate":"2007-01","conditions":["Chronic Liver Disease","TB"],"enrollment":0,"completionDate":""},{"nctId":"NCT04347876","phase":"","title":"Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-04-11","conditions":["COVID-19","BCG Vaccination"],"enrollment":100,"completionDate":"2020-06-30"},{"nctId":"NCT04288817","phase":"PHASE3","title":"Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common Warts","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-03-01","conditions":["Common Wart"],"enrollment":40,"completionDate":"2021-05-01"},{"nctId":"NCT02119130","phase":"NA","title":"Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-11-01","conditions":["Latent Tuberculosis","HIV"],"enrollment":3506,"completionDate":"2019-05"},{"nctId":"NCT04073108","phase":"","title":"Causes of FUO in Infants and Children","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-10-01","conditions":["Fever of Unknown Origin"],"enrollment":50,"completionDate":"2021-10-01"},{"nctId":"NCT02073669","phase":"NA","title":"Latent Tuberculosis in Second Generation Immigrants From High Risk Countries Compare to Low-risk Young Israeli Adults","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2014-03","conditions":["Latent Tuberculosis"],"enrollment":115,"completionDate":"2018-11"},{"nctId":"NCT03717025","phase":"NA","title":"Comparison of Surgical Methods on Resistant Sites in Stable Vitiligo Patients","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2017-07-01","conditions":["Vitiligo"],"enrollment":20,"completionDate":"2018-11"},{"nctId":"NCT03668834","phase":"NA","title":"Comparing Recipient Site Preparation Using Dermabrasion, Dermaroller and Liquid Nitrogen Induced Blister in Non Cultured Epidermal Cell Suspension in Stable Vitiligo","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2018-01-01","conditions":["Vitiligo"],"enrollment":36,"completionDate":"2019-06-30"},{"nctId":"NCT02255136","phase":"NA","title":"Efficacy Study of Homeopathic Medicines in Treatment of Allergic Rhinitis and/or Induced Bronchial Asthma","status":"COMPLETED","sponsor":"Mahesh Bhattacharyya Homoeopathic Medical College and Hospital","startDate":"2012-03","conditions":["Rhinitis; Allergic, With Asthma"],"enrollment":100,"completionDate":"2018-04"},{"nctId":"NCT02332889","phase":"PHASE1,PHASE2","title":"Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs","status":"TERMINATED","sponsor":"University of Louisville","startDate":"2015-04","conditions":["Gliomas","Medulloblastoma","Neuroectodermal Tumors, Primitive"],"enrollment":1,"completionDate":"2016-07"},{"nctId":"NCT00257907","phase":"","title":"Immune Response to Mycobacterium Tuberculosis Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-11-18","conditions":["Latent Tuberculosis"],"enrollment":157,"completionDate":"2016-02-24"},{"nctId":"NCT03477448","phase":"PHASE4","title":"The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-04-01","conditions":["Warts"],"enrollment":40,"completionDate":"2020-04-01"},{"nctId":"NCT02712671","phase":"","title":"Testing for Tuberculosis in the United Kingdom HIV Infected Population","status":"UNKNOWN","sponsor":"University College, London","startDate":"2013-06","conditions":["HIV","Latent Tuberculosis"],"enrollment":300,"completionDate":"2024-09"},{"nctId":"NCT03153566","phase":"PHASE3","title":"Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-06-01","conditions":["Genital Wart"],"enrollment":45,"completionDate":"2018-12"},{"nctId":"NCT03156855","phase":"PHASE4","title":"Sequential Therapy Versus Quadruple Therapy in H. Pylori Eradication","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2015-09","conditions":["Helicobacter"],"enrollment":620,"completionDate":"2019-12"},{"nctId":"NCT01910662","phase":"PHASE1","title":"Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-22","conditions":["Dermatitis"],"enrollment":24,"completionDate":"2013-11-26"},{"nctId":"NCT03095144","phase":"","title":"Spinal Anesthesia and General Anesthesia for Pyloromyotomy - Surgical Outcomes a Comparison Retrospective Study","status":"UNKNOWN","sponsor":"Bnai Zion Medical Center","startDate":"2017-05","conditions":["Hypertrophic Pyloric Stenosis","Spinal Anesthesia","General Anesthesia"],"enrollment":100,"completionDate":"2017-12"},{"nctId":"NCT01119521","phase":"PHASE1","title":"Study of Pre-clearance of Latent Tuberculosis Infection And BCG Revaccination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-10","conditions":["Tuberculosis"],"enrollment":82,"completionDate":"2013-07"},{"nctId":"NCT02255682","phase":"PHASE4","title":"Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2015-01","conditions":["Cardiovascular Disease","Diabetes Mellitus"],"enrollment":35,"completionDate":"2016-12"},{"nctId":"NCT02521610","phase":"PHASE1","title":"A Multiple Ascending-Dose Study of RG7625 in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-08","conditions":["Healthy Volunteer"],"enrollment":33,"completionDate":"2015-11"},{"nctId":"NCT01223534","phase":"PHASE4","title":"QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2010-07","conditions":["Latent Tuberculosis Infection"],"enrollment":871,"completionDate":"2016-02"},{"nctId":"NCT02353650","phase":"NA","title":"The Effect of Coenzyme Q10 on Hearing and Tinnitus Characteristics of Chronic Tinnitus Patients","status":"UNKNOWN","sponsor":"University Hospital, Antwerp","startDate":"2014-11","conditions":["Tinnitus"],"enrollment":0,"completionDate":""},{"nctId":"NCT01642888","phase":"PHASE3","title":"A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2012-09","conditions":["Tuberculosis"],"enrollment":1190,"completionDate":"2014-09"},{"nctId":"NCT00707317","phase":"","title":"T Cell Interferon-gamma Release Assay (TIGRA) in Immunocompromised Individuals","status":"COMPLETED","sponsor":"Tuberculosis Network European Trialsgroup","startDate":"2008-06","conditions":["Tuberculosis","Monitoring, Immunologic"],"enrollment":1843,"completionDate":"2011-05"},{"nctId":"NCT01674205","phase":"PHASE1","title":"Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-09","conditions":["Influenza, Human"],"enrollment":36,"completionDate":"2013-06"},{"nctId":"NCT01331811","phase":"NA","title":"Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2011-04","conditions":["HIV","Tuberculosis","Pediatrics"],"enrollment":441,"completionDate":"2014-05"},{"nctId":"NCT01241188","phase":"PHASE2","title":"A Trial of the C-Tb Skin Test, When Given Intradermally to Adult Patients Recently Diagnosed With Active Tuberculosis (TB)","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2011-04","conditions":["Tuberculosis"],"enrollment":253,"completionDate":"2011-12"},{"nctId":"NCT01779102","phase":"PHASE2,PHASE3","title":"Safety Study Investigating if Concomitant Injections of C-Tb and 2 T.U Tuberculin Affect Induration Responses","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2013-10","conditions":["Tuberculosis"],"enrollment":456,"completionDate":"2014-09"},{"nctId":"NCT01631266","phase":"PHASE3","title":"Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSI","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2012-07","conditions":["Tuberculosis"],"enrollment":979,"completionDate":"2014-10"},{"nctId":"NCT02329730","phase":"PHASE2","title":"Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2014-02","conditions":["Tuberculosis"],"enrollment":144,"completionDate":"2014-08"},{"nctId":"NCT00128193","phase":"PHASE2","title":"Leprosy Skin Test Antigens Trial","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-04","conditions":["Leprosy"],"enrollment":260,"completionDate":"2009-09"},{"nctId":"NCT00173433","phase":"","title":"Exogenous Reinfection of Tuberculosis in Taiwan","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2005-08","conditions":["Tuberculosis"],"enrollment":150,"completionDate":"2006-07"},{"nctId":"NCT00756808","phase":"","title":"Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis (TB) in Elderly Residents of Nursing Homes?","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2007-10","conditions":["Tuberculosis"],"enrollment":135,"completionDate":"2010-07"},{"nctId":"NCT00811343","phase":"NA","title":"Impact of New Immunological Diagnosis Tests of Latent Tuberculosis Before Anti TNF Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-12","conditions":["Tuberculosis"],"enrollment":430,"completionDate":"2012-06"},{"nctId":"NCT00565019","phase":"PHASE3","title":"Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Dupuytren's Contracture","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2007-11","conditions":["Dupuytren's Contracture"],"enrollment":51,"completionDate":"2013-06"},{"nctId":"NCT01850043","phase":"","title":"The Epidemiology of TST Change in Korea","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2005-05","conditions":["Tuberculosis","Latent Tuberculosis"],"enrollment":5552,"completionDate":"2012-05"},{"nctId":"NCT00942721","phase":"PHASE1","title":"Cognitive Behavioral Therapy Delivered Over the Internet for Women With Postpartum Depression","status":"COMPLETED","sponsor":"Oregon Research Institute","startDate":"2009-10","conditions":["Postpartum Depression"],"enrollment":53,"completionDate":"2013-04"},{"nctId":"NCT00000955","phase":"NA","title":"Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections","Tuberculosis"],"enrollment":864,"completionDate":"1992-12"},{"nctId":"NCT00589953","phase":"PHASE2","title":"High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study","status":"TERMINATED","sponsor":"Atlantic Health System","startDate":"2007-07","conditions":["Infant, Premature","Erythropoietin","Brain Injury","Intraventricular Hemorrhage","Periventricular Leukomalacia","Neurodevelopmental Outcomes","Randomized Clinical Trial"],"enrollment":22,"completionDate":"2010-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intradermal"},"crossReferences":{"UNII":"I7L8FKN87J","RXCUI":"313532,798408","SPL_ID":"a97e057f-6554-4ce2-bc75-3ebc1978e0d0","chemblId":"CHEMBL2108161"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"ENDO USA, Inc.","relationship":"Original Developer"}],"publicationCount":16749,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"originalDeveloper":"ENDO USA, Inc.","recentPublications":[{"date":"2026 Mar 30","pmid":"41910258","title":"From T-cell sensitization to molecular-intelligent stratification: a roadmap for precision diagnosis of latent tuberculosis infection.","journal":"Clinical microbiology reviews"},{"date":"2026","pmid":"41908889","title":"Isolated ovarian tuberculosis in a hemodialysis patient: An incidental pre-transplant discovery with diagnostic and management implications.","journal":"IDCases"},{"date":"2026 Mar 25","pmid":"41906503","title":"The potential of ancient medicine - using products from snails in treatment of oncology patients.","journal":"Annals of agricultural and environmental medicine : AAEM"},{"date":"2026 Mar 13","pmid":"41898483","title":"Delayed-Type Hypersensitivity to Mycobacterium tuberculosis Antigens: The Immunological Mechanism and Potential Therapeutic Strategies-A Systematic Review.","journal":"International journal of molecular sciences"},{"date":"2026 Mar 23","pmid":"41897686","title":"Comparative Diagnostic Performance of TST and IGRAs in the Diagnosis of Latent Tuberculosis Infection: A Systematic Review and Diagnostic Meta-Analysis.","journal":"Diagnostics (Basel, Switzerland)"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"ENDO USA, Inc.","companyId":"endo-usa-inc","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:14:57.996172+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}